Our data provide evidence that there may be a significant cross-talk between the VEGF/R and PD-1 pathway in GEP-NENs; this observation will add a scientific rationale for investigating combination approaches, as recently shown in hepatocellular carcinoma for the efficacy of the novel combination of bevacizumab and atezolizumab [17]. Here, VEGFA is linked to hepatocellular carcinoma.